project id: TCGA-UCEC; case submitter id: TCGA-AX-A2HF; source center: 23; state: released; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 8.1; age at index: 67; days to birth: -24689; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1943; age at diagnosis: 24689; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 848.0; figo stage: Stage IB; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: Not Reported; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 440; initial weight: 140.0; oct embedded: false; preservation method: Unknown; sample id: 137e9776-ca5c-47f3-9ef7-8726d021fbb2; sample submitter id: TCGA-AX-A2HF-01A; portion id: 02490372-8dfd-4f56-860b-a93a901453c3; portion submitter id: TCGA-AX-A2HF-01A-11; slide id: bbbb2b1a-2a3b-4583-bd26-5b46adcab7d6; slide submitter id: TCGA-AX-A2HF-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 2.0; percent tumor cells: 96.0; percent tumor nuclei: 98.0; section location: TOP;